Hosted on MSN12d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
Datroway is the second ADC developed by the pharmaceutical companies Daiichi Sankyo and AstraZeneca to get FDA approval.
FiercePharma6d
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
PMLiVE5d
Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...
MedCity News1mon
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer
Last week, the FDA accepted an application seeking approval of the ADC for EGFR-mutated non-small cell lung cancer. A regulatory decision in this indication is expected in the third quarter of ...
BioWorld29d
FDA approves Daiichi Sankyo’s Trop-2 ADC for breast cancer
Marking the second global approval after Japan, the U.S. FDA has approved Datroway (datopotamab deruxtecan), a trophoblast cell surface antigen 2-directed antibody-drug conjugate (ADC) from Daiichi ...
FiercePharma4d
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
The American Journal of Managed Care4d
TROPION-Breast01: Datopotamab Deruxtecan Improves Progression-Free Survival
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...